Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Monogenic interleukin-10 (IL-10) and IL-10 receptor (IL-10R) deficiencies cause very early onset severe inflammatory bowel disease.
|
24089328 |
2013 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Additionally, clinical experience using interleukin 10-secreting <i>Lc. lactis</i> has been shown to be safe and to facilitate biological containment in IBD therapy.
|
28179904 |
2017 |
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor.
|
19890111 |
2009 |
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The associations in IL10 and IL18R1 are shared with inflammatory bowel disease, suggesting common etiologic pathways.
|
25200001 |
2015 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Through plasma-induced signature analysis, we have defined a unique, partially TGF-β/IL-10-dependent immunoregulatory signature associated with IBD that may prove useful in predicting therapeutic responsiveness.
|
26660358 |
2016 |
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Therefore, polymorphisms of the IL-10 gene are not demonstrably involved in the predisposition of IBD in our cohorts of patients.
|
11271474 |
2000 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Interleukin-10 (IL-10) has a key role in regulating mucosal inflammation in inflammatory bowel disease.
|
16566641 |
2006 |
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This suggests that individuals genetically predisposed to produce less IL-10 are at a higher risk of developing IBD, in particular, UC.
|
10551422 |
1999 |
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
These results indicate that both the <i>IL-10</i> gene itself, and through epistatic interaction with genes within the IL-10/STAT3 signaling pathway, contribute to the risk of pediatric IBD.
|
28785144 |
2017 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Here, we review recent findings on how IL10- and IL10R-dependent signaling modulates innate and adaptive immune responses in the murine gastrointestinal tract, with implications of their role in the prevention of inflammatory bowel disease (IBD).
|
24507158 |
2014 |
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The role of functional polymorphisms at positions -627 and -1117 in the IL-10 gene as candidate susceptibility loci in inflammatory bowel disease and their importance in determining disease extent were evaluated in 159 patients with ulcerative colitis (83 left-sided; 76 extensive), 90 patients with Crohn's disease (22 small bowel; 29 large bowel; 39 both), and 227 controls.
|
11478505 |
2001 |
Inflammatory Bowel Diseases
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Interleukin 10 promoter region polymorphisms in inflammatory bowel disease in Tunisian population.
|
19184348 |
2009 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
We report that IL-10(-/-) mice, a widely accepted mouse model of IBD, crossed to human MUC1-transgenic mice, develop MUC1(+) IBD characterized by an earlier age of onset, higher inflammation scores, and a much higher incidence and number of colon cancers compared with IL-10(-/-) mice.
|
17617560 |
2007 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
IL-10(-/-) mice, an animal model of Th1-mediated inflammatory bowel disease, were screened for the expression of 600 microRNAs (miRNAs) using colonic tissues and PBLs from animals having either mild inflammation or severe intestinal inflammation.
|
22043014 |
2011 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
All eight TYK2-deficient patients displayed impaired but not abolished cellular responses to (a) IL-12 and IFN-α/β, accounting for mycobacterial and viral infections, respectively; (b) IL-23, with normal proportions of circulating IL-17(+) T cells, accounting for their apparent lack of mucocutaneous candidiasis; and (c) IL-10, with no overt clinical consequences, including a lack of inflammatory bowel disease.
|
26304966 |
2015 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
We performed direct gene sequencing looking for 94 variations in NOD2, ATG16L1, IL23R, IL10R, IL10 and XIAP genes previously shown as correlated with IBD both in multifactorial and in Mendelian models.
|
29248579 |
2018 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Genetic and candidate gene analyses in an Il10-deficient IBD mouse model system identified Cd14 as a potentially protective candidate gene.
|
28411859 |
2017 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
The anti-inflammatory cytokine IL-10 dampens intestinal inflammation and is therefore a good candidate gene for IBD.
|
25004811 |
2014 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
Here, we show that in a murine inflammatory bowel disease (IBD) model based on macrophage-restricted interleukin-10 (IL-10) receptor deficiency (<i>Cx3cr1<sup>Cre</sup>:Il10ra<sup>fl/fl</sup></i> mice), proinflammatory mutant gut macrophages cause severe spontaneous colitis resembling the condition observed in children carrying IL-10R mutations.
|
31201258 |
2019 |
Inflammatory Bowel Diseases
|
0.700 |
AlteredExpression
|
group |
BEFREE |
cAT-MSC-secreted TSG-6 ameliorated IBD and regulated colonic expression of pro- and anti-inflammatory cytokines such as tumor necrosis factor-α, interleukin-6, and interleukin-10.
|
29625582 |
2018 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
In conclusion, reference drugs with known efficacy in severe inflammatory bowel disease were efficacious in the PAC IL-10 k.o. model.
|
24797915 |
2014 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
ELISA assay and the peripheral blood mononuclear cell (PBMC) cytokine mRNA expression levels were evaluated by quantitative SYBR Green real-time RT-PCR to determine the IL-1beta, TNF-alpha, IFN-gamma and IL-10 secretion in inflammatory bowel diseases patients' PBMC culture supernatants.
|
20138213 |
2010 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
CTD_human |
AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice.
|
27783946 |
2016 |
Inflammatory Bowel Diseases
|
0.700 |
Biomarker
|
group |
BEFREE |
However, little is known regarding the role of PI3Kδ on IL-10-producing B cells that help regulate mucosal inflammation in IBD.
|
31546615 |
2019 |
Inflammatory Bowel Diseases
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Consistent with the PBMC data, both <i>L. fermentum</i> KBL374- and KBL375-treated DSS mice demonstrated decreased Th1-, Th2-, and Th17-related cytokine levels and increased IL-10 in the colon compared with the DSS control mice.Administration of <i>L. fermentum</i> KBL374 or KBL375 to mice increased the CD4+CD25+Foxp3+Treg cell population in mesenteric lymph nodes.Additionally, <i>L. fermentum</i> KBL374 or KBL375 administration reshaped and increased the diversity of the gut microbiota.In particular, <i>L. fermentum</i> KBL375 increased the abundance of beneficial microorganisms, such as <i>Lactobacillus</i> spp. and <i>Akkermansia</i> spp.Both <i>L. fermentum</i> KBL374 and KBL375 may alleviate inflammatory diseases, such as inflammatory bowel disease, in the gut by regulating immune responses and altering the composition of gut microbiota.
|
30939976 |
2019 |